Nevro Corp
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well a… Read more
Nevro Corp - Asset Resilience Ratio
Nevro Corp (NVRO) has an Asset Resilience Ratio of 35.75% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Nevro Corp's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Nevro Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $198.00 Million | 35.75% |
| Total Liquid Assets | $198.00 Million | 35.75% |
Asset Resilience Insights
- Very High Liquidity: Nevro Corp maintains exceptional liquid asset reserves at 35.75% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nevro Corp Industry Peers by Asset Resilience Ratio
Compare Nevro Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022 |
Medical Devices | 0.01% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.26% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 7.79% |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932 |
Medical Devices | 6.64% |
|
Shinhung
KO:004080 |
Medical Devices | 4.17% |
|
UMediC Group Berhad
KLSE:0256 |
Medical Devices | 1.48% |
|
Osang Healthcare Co.,Ltd
KQ:036220 |
Medical Devices | 9.34% |
|
HansBiomed Corporation
KQ:042520 |
Medical Devices | 9.13% |
Annual Asset Resilience Ratio for Nevro Corp (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Nevro Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 35.75% | $198.00 Million | $553.84 Million | +1.38pp |
| 2023-12-31 | 34.37% | $218.51 Million | $635.71 Million | -7.79pp |
| 2022-12-31 | 42.17% | $254.01 Million | $602.41 Million | -14.80pp |
| 2021-12-31 | 56.97% | $327.32 Million | $574.54 Million | -11.86pp |
| 2020-12-31 | 68.83% | $543.37 Million | $789.43 Million | +32.12pp |
| 2019-12-31 | 36.71% | $172.43 Million | $469.64 Million | -9.34pp |
| 2018-12-31 | 46.05% | $213.28 Million | $463.12 Million | -3.82pp |
| 2017-12-31 | 49.88% | $226.47 Million | $454.06 Million | -4.69pp |
| 2016-12-31 | 54.57% | $234.95 Million | $430.58 Million | +17.94pp |
| 2015-12-31 | 36.62% | $106.63 Million | $291.18 Million | -38.21pp |
| 2014-12-31 | 74.83% | $151.52 Million | $202.50 Million | +16.32pp |
| 2013-12-31 | 58.51% | $44.12 Million | $75.41 Million | +7.61pp |
| 2012-12-31 | 50.90% | $25.00 Million | $49.11 Million | -- |